BB-2516 oral inhibitor of matrix metalloproteinase: Will begin shortly a Phase II U.S. trial in ovarian cancer. A U.K. Phase II trial in ovarian and colorectal

By WIR Staff | Mar 27, 1995 | 8:00 AM GMT

British Biotech plc (BBIOY), Oxford, U.K.

Read the full 62 word article

How to gain access

Continue reading with a
two-week free trial.